Experimental vaccine for common cancer shows potential in clinical trial; here’s what we know
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 clinical trial results reveal an immune response in half of the participants, with a sustained effect for up to four years. The encouraging findings prompt plans for larger studies to confirm effectiveness.
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 clinical trial results reveal an immune response in half of the participants, with a sustained effect for up to four years. The encouraging findings prompt plans for larger studies to confirm effectiveness.
